CTU: A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors.

  • Park, John (Primary Chief Investigator)
  • TAIDI, Gina (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Contacos, Christine (Clinical Trial Unit Staff)
  • Martin, Lewis (Clinical Trial Unit Staff)
  • Chester, Catherine (Clinical Trial Unit Staff)

Project: Research

Project Details

Short titleBGB-A317-26808-101
StatusActive
Effective start/end date21/12/23 → 30/11/28